Skip to main content

CARACTERIZACION MOLECULAR DE CELULAS DENDRITICAS TOLEROGENICAS EN CONDICIONES DE INFLAMACION CRONICA. DEL LABORATORIO A LA CLINICA, Y VUELTA AL LABORATORIO

PI20/01313

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Execution centre INSTITUTO DE INVESTIGACION GERMANS TRIAS I PUJOL (IGTP)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosis

  • Fondelli, Federico|||0000-0002-6875-4744
  • Willemyns, Jana|||0000-0001-6325-9309
  • Domenech-Garcia, Roger|||0009-0002-5742-566X
  • Mansilla, Maria José
  • Godoy-Tena, Gerard|||0000-0003-3832-5794
  • Ferreté-Bonastre, Anna G.|||0000-0003-3327-6129
  • Agúndez-Moreno, Alex|||0009-0000-9524-235X
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Ballestar, Esteban|||0000-0002-1400-2440
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
Multiple sclerosis (MS) is a chronic disease characterized by dysregulated self-reactive immune responses that damage the neurons' myelin sheath, leading to progressive disability. The primary therapeutic option, immunosuppressants, inhibits pathogenic anti-myelin responses but depresses the immune system. Antigen-specific monocyte-derived autologous tolerogenic dendritic cells (tolDCs) offer alternative therapeutic approaches to restore tolerance to autoantigens without causing generalized immunosuppression. However, immune dysregulation in MS could impact the properties of the monocytes used as starting material for this cell therapy. Here, we characterized CD14+ monocytes, mature dendritic cells, and vitamin D3-tolDCs (VitD3-tolDCs) from active, treatment-naive MS patients and healthy donors (HDs). Using multiomics, we identified a switch in these cell types toward proinflammatory features characterized by alterations in the aryl hydrocarbon receptor (AhR) and NF-κB pathways. MS patient-derived VitD3-tolDCs showed reduced tolerogenic properties compared with those from HDs, which were fully restored through direct AhR agonism and by use of in vivo or in vitro dimethyl fumarate (DMF) supplementation. Additionally, in the experimental autoimmune encephalomyelitis mouse model, combined therapy of DMF and VitD3-tolDCs was more efficient than monotherapies in reducing the clinical score of mice. We propose that a combined therapy with DMF and VitD3-tolDCs offers enhanced therapeutic potential in treating MS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis

  • Quirant, Bibiana|||0000-0002-3875-8074
  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Navarro-Barriuso, Juan|||0000-0003-2884-4961
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Fondelli, Federico|||0000-0002-6875-4744
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
Autologous antigen-specific therapies based on tolerogenic dendritic cells (tolDC) offer the possibility to treat autoimmune diseases by restoring homeostasis and targeting specifically autoreactive responses. Here, we explore the hypothesis that systemic inflammation occurring in autoimmune diseases, such as multiple sclerosis (MS), can generate a disease-specific environment able to alter the functionality of tolDC. In this context in fact, a combined therapy of tolDC with an immunomodulatory treatment could potentiate the beneficial effect of this antigen-specific cell therapy. For this purpose, we analyzed the efficacy of a combined therapy based on the use of vitamin D3 (VitD3)-tolDC plus interferon beta (IFN-beta) in MS. VitD3-tolDC were generated from healthy donors and MS patients and co-cultured with allogeneic peripheral blood mononuclear cells, in the presence or absence of IFN-beta. In vitro, VitD3-tolDC treatment reduced the percentage of activated T cells and allogeneic proliferation, whereas VitD3-tolDC+IFN-beta treatment enhanced the suppressive ability of VitD3-tolDC and, additionally, induced a shift towards a Th2 profile. To determine the clinical benefit of the combined therapy, C57BL/6-experimental autoimmune encephalomyelitis (EAE)-induced mice were treated with antigen-specific VitD3-tolDC and/or IFN-beta. Treatment of EAE mice with combined therapy ameliorated the disease course compared to each monotherapy. These results suggest that a combined therapy based on antigen-specific VitD3-tolDC and IFN-beta may represent a promising strategy for MS patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Identifying Changes in Peripheral Lymphocyte Subpopulations in Adult Onset Type 1 Diabetes

  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Pizarro, Eduarda
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Fernández, Marco A.|||0000-0002-3921-2209
  • Vives Pi, Marta|||0000-0003-3735-0779
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
T- and B-lymphocytes play an important role in the pathogenesis of type 1 diabetes (T1D), a chronic disease caused by the autoimmune destruction of the insulin-producing cells in the pancreatic islets. Flow cytometry allows their characterization in peripheral blood, letting to investigate changes in cellular subpopulations that can provide insights in T1D pathophysiology. With this purpose, CD4 + and CD8 + T cells (including naïve, central memory, effector memory and terminally differentiated effector (TEMRA), Th17 and Tregs) and B cells subsets (naïve, unswitched memory, switched memory and transitional B cells) were analysed in peripheral blood of adult T1D patients at disease onset and after ≥2 years using multiparametric flow cytometry. Here we report changes in the percentage of early and late effector memory CD4 + and CD8 + T cells as well as of naïve subsets, regulatory T cells and transitional B cells in peripheral blood of adult patients at onset of T1D when compared with HD. After 2 years follow-up these changes were maintained. Also, we found a decrease in percentage of Th17 and numbers of T cells with baseline. In order to identify potential biomarkers of disease, ROC curves were performed being late EM CD4 T cell subset the most promising candidate. In conclusion, the observed changes in the percentage and/or absolute number of lymphocyte subpopulations of adult T1D patients support the hypothesis that effector cells migrate to the pancreas and this autoimmune process perseveres along the disease. Moreover, multiparametric flow allows to identify those subsets with potential to be considered biomarkers of disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Paving the way towards an effective treatment for multiple sclerosis, advances in cell therapy

  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • González-Larreategui, Íñigo|||0000-0002-0959-8497
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Fondelli, Federico|||0000-0002-6875-4744
  • Djedovic, Neda
  • Iwaszkiewicz-Grzes, Dorota|||0000-0003-1177-1874
  • Chwojnicki, K.
  • Miljković, Đ.
  • Trzonkowski, P.
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to middle-aged adults, affecting ~2.5 million people worldwide. Currently, most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs, but these drugs are unable to halt or reverse the disease and have the potential to cause serious adverse events. Hence, there is an urgent need for the development of next-generation treatments that, alone or in combination, stop the undesired autoimmune response and contribute to the restoration of homeostasis. This review analyzes current MS treatments as well as different cell-based therapies that have been proposed to restore homeostasis in MS patients (tolerogenic dendritic cells, regulatory T cells, mesenchymal stem cells, and vaccination with T cells). Data collected from preclinical studies performed in the experimental autoimmune encephalomyelitis (EAE) model of MS in animals, in vitro cultures of cells from MS patients and the initial results of phase I/II clinical trials are analyzed to better understand which parameters are relevant for obtaining an efficient cell-based therapy for MS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Vitamin D receptor, STAT3, and TET2 cooperate to establish tolerogenesis

  • Català-Moll, Francesc|||0000-0002-2354-8648
  • Ferreté-Bonastre, Anna G|||0000-0003-3327-6129
  • Godoy-Tena, Gerard|||0000-0003-3832-5794
  • Morante-Palacios, Octavio|||0000-0002-6435-2756
  • Ciudad, Laura|||0000-0002-5219-6792
  • Barberà, Laura|||0000-0002-0883-657X
  • Fondelli, Federico|||0000-0002-6875-4744
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Li, Tianlu|||0000-0001-7152-4870
  • Ballestar, Esteban|||0000-0002-1400-2440
The active form of vitamin D, 1,25-dihydroxyvitamin D3, induces a stable tolerogenic phenotype in dendritic cells (DCs). This process involves the vitamin D receptor (VDR), which translocates to the nucleus, binds its cognate genomic sites, and promotes epigenetic and transcriptional remodeling. In this study, we report the occurrence of vitamin D-specific DNA demethylation and transcriptional activation at VDR binding sites associated with the acquisition of tolerogenesis in vitro. Differentiation to tolerogenic DCs associates with activation of the IL-6-JAK-STAT3 pathway. We show that JAK2-mediated STAT3 phosphorylation is specific to vitamin D stimulation. VDR and the phosphorylated form of STAT3 interact with each other to form a complex with methylcytosine dioxygenase TET2. Most importantly, pharmacological inhibition of JAK2 reverts vitamin D-induced tolerogenic properties of DCs. This interplay among VDR, STAT3, and TET2 opens up possibilities for modulating DC immunogenic properties in clinics.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Transfection of Vitamin D3-Induced Tolerogenic Dendritic Cells for the Silencing of Potential Tolerogenic Genes. Identification of CSF1R-CSF1 Signaling as a Glycolytic Regulator

  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • González-Larreategui, Íñigo|||0000-0002-0959-8497
  • Figa-Martín, Neus
  • Barallat, Jaume|||0000-0003-3493-5958
  • Fondelli, Federico|||0000-0002-6875-4744
  • Sellés-Rius, Ares|||0000-0002-9745-7749
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
The use of autologous tolerogenic dendritic cells (tolDC) has become a promising strategy to re-establish immune tolerance in autoimmune diseases. Among the different strategies available, the use of vitamin D3 for the generation of tolDC (VitD3-tolDC) has been widely tested because of their immune regulatory properties. To identify molecules and pathways involved in the generation of VitD3-tolDC, we established an easy and fast gene silencing method based on the use of Viromer blue to introduce siRNA into monocytes on day 1 of culture differentiation. The analysis of the effect of CD209 (DC-SIGN) and CD115 (CSF1R) down-modulation on the phenotype and functionality of transfected VitD3-tolDC revealed a partial role of CD115 in their tolerogenicity. Further investigations showed that CSF1R-CSF1 signaling is involved in the induction of cell metabolic reprogramming, triggering glycolysis to produce high amounts of lactate, a novel suppressive mechanism of T cell proliferation, recently found in autologous tolerogenic dendritic cells (ATDCs).